DUBLIN–(BUSINESS WIRE)–The “Biologics Market – Growth, Trends, and Forecast (2020 – 2025)” report has been added to ResearchAndMarkets.com’s offering.

The biologics market is majorly driven by growing capital investment from the key market players, the rise in the burden of chronic diseases, loss of patent exclusivity of the leading biologic drugs, and growing demand and higher acceptability for innovative therapies

The success of biologic drugs in the treatment of major chronic diseases, notably cancer and autoimmune diseases, has enabled big pharmaceutical companies, like Eli Lilly and Company, Bristol-Myers Squibb, Novartis, AstraZeneca, and GlaxoSmithKline (GSK), to invest in these products. In 2019 there were three biological drugs that were approved by the United States Food and Drug Administration (FDA), one of which is an anticoagulant solution by Griffols.

Furthermore, increasing demand for biologics proves efficient in treating rheumatoid arthritis and Crohn’s disease boosting the market even further.

Key Market Trends

Monoclonal Antibodies Segment is Expected to Dominate Over the Forecast Period

The monoclonal antibodies (mABs) segment held a maximum share due to the higher usage of this category of drugs in different therapeutic areas. mABs allow targeting of unhealthy cells without harming the healthy cells. Also, these drugs are used in the management and treatment of diseases, including cancer and autoimmune disorder. The increasing prevalence of cancer and other chronic diseases have resulted in increasing demand for monoclonal antibodies, which in turn is leading to the demand for biologics. Rising research and development activities in genomics alongside the emergence of technologically advanced genetic platforms, such as next-generation sequencing, have also majorly contributed to the market

North America holds the Largest Market Share and is Believed to Follow the Same Trend over the Forecast Period

The North American healthcare biologics market dominated the global market and is estimated to show a similar trend during the forecast period. Factors augmenting the growth of biologics are increasing incidences of chronic diseases, the presence of well-established pharmaceutical companies, and an increase in the number of biotech companies. Furthermore, the presence of well-established companies, like Johnson & Johnson, Bristol-Myers Squibb, AbbVie Inc., and other key players, is making biologics more accessible in the United States. The US’s Johnson & Johnson is in the lead, closely followed by the Swiss company Hoffman-La Roche. Government initiative for the awareness of biologics is further expected to spur the growth of the market in North America.

Key Topics Covered:

1 INTRODUCTION

1.1 Study Deliverables

1.2 Study Assumptions

1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

4.1 Market Overview

4.2 Market Drivers

4.2.1 Growing Capital Investment from Key Market Players

4.2.2 Rise in the Prevalence of Chronic Diseases

4.2.3 Loss of Patent Exclusivity of the Leading Biologic Drugs

4.2.4 Growing Demand and Higher Acceptability for Innovative Therapies

4.3 Market Restraints

4.3.1 Stringent Regulatory Process and Initial High Capital Investment

4.3.2 Rising Control and Cost for Accessing Biologics

4.4 Porter’s Five Forces Analysis

4.4.1 Threat of New Entrants

4.4.2 Bargaining Power of Buyers/Consumers

4.4.3 Bargaining Power of Suppliers

4.4.4 Threat of Substitute Products

4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

5.1 By Product

5.1.1 Monoclonal Antibodies

5.1.2 Vaccines

5.1.3 Recombinant Hormones/Proteins

5.1.4 Cellular Based Biologics

5.1.5 Gene Based Biologics

5.1.6 Other Products

5.2 By Application

5.2.1 Cancer Diseases

5.2.2 Infectious Diseases

5.2.3 Autoimmune Diseases

5.2.4 Other Applications

5.3 Geography

5.3.1 North America

5.3.1.1 United States

5.3.1.2 Canada

5.3.1.3 Mexico

5.3.2 Europe

5.3.2.1 Germany

5.3.2.2 United Kingdom

5.3.2.3 France

5.3.2.4 Italy

5.3.2.5 Spain

5.3.2.6 Rest of Europe

5.3.3 Asia-Pacific

5.3.3.1 China

5.3.3.2 Japan

5.3.3.3 India

5.3.3.4 Australia

5.3.3.5 South Korea

5.3.3.6 Rest of Asia-Pacific

5.3.4 Middle-East & Africa

5.3.4.1 GCC

5.3.4.2 South Africa

5.3.4.3 Rest of Middle-East & Africa

5.3.5 South America

5.3.5.1 Brazil

5.3.5.2 Argentina

5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

6.1 Company Profiles

6.1.1 AbbVie Inc.

6.1.2 Amgen, Inc.

6.1.3 Eli Lilly and Company

6.1.4 F. Hoffmann-La Roche AG

6.1.5 GlaxoSmithKline PLC

6.1.6 Johnson & Johnson

6.1.7 Merck & Co.

6.1.8 Novo Nordisk A/S

6.1.9 Pfizer Inc.

6.1.10 Sanofi SA

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

For more information about this report visit https://www.researchandmarkets.com/r/ja2u2s